Just over a month after it was approved in the UK, AstraZeneca and Ionis' Wainzua has been recommended for NHS use in the treatment of patients with polyneuropathy associated with transthyretin ...
AstraZeneca and Ionis are planning a US launch next month for Wainua, their treatment for polyneuropathy in life-threatening disease transthyretin-mediated amyloidosis (ATTR), after getting FDA ...
Chronic inflammatory demyelinating polyneuropathy (CIDP) treatment aims to slow immune-driven demyelination and reduce inflammation. This can help protect nerve signaling and function. First-line CIDP ...
Myelin is the protective coating around nerves that helps electrical messages travel properly. When it is damaged, movement, vision, and fatigue can worsen. Demyelinating disease can affect the ...
Guillain-Barré Syndrome (GBS) is a rare autoimmune disease that affects the nervous system, causing muscle weakness, paralysis, and lack of sensitivity. In addition to drug treatment, physical therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results